Phenotypic Screen Identifies JAK2 as a Major Regulator of FAT10 Expression.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
20 12 2019
Historique:
pubmed: 4 12 2019
medline: 3 4 2020
entrez: 4 12 2019
Statut: ppublish

Résumé

FAT10 is a ubiquitin-like protein suggested to target proteins for proteasomal degradation. It is highly upregulated upon pro-inflammatory cytokines, namely, TNFα, IFNγ, and IL6, and was found to be highly expressed in various epithelial cancers. Evidence suggests that FAT10 is involved in cancer development and may have a pro-tumorigenic role. However, its biological role is still unclear, as well as its biochemical and cellular regulation. To identify pathways underlying FAT10 expression in the context of pro-inflammatory stimulation, which characterizes the cancerous environment, we implemented a phenotypic transcriptional reporter screen with a library of annotated compounds. We identified AZ960, a potent JAK2 inhibitor, which significantly downregulates FAT10 under pro-inflammatory cytokines induction, in an NFκB-independent manner. We validated JAK2 as a major regulator of FAT10 expression via knockdown, and we suggest that the transcriptional effects are mediated through pSTAT1/3/5. Overall, we have elucidated a pathway regulating FAT10 transcription and discovered a tool compound to chemically downregulate FAT10 expression, and to further study its biology.

Identifiants

pubmed: 31794190
doi: 10.1021/acschembio.9b00667
doi:

Substances chimiques

5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile 0
Aminopyridines 0
Protein Kinase Inhibitors 0
Pyrazoles 0
UBD protein, human 0
Ubiquitins 0
JAK2 protein, human EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2538-2545

Auteurs

Nava Reznik (N)

Department of Immunology , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.
Department of Organic Chemistry , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.

Noga Kozer (N)

Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.

Avital Eisenberg-Lerner (A)

Department of Immunology , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.

Haim Barr (H)

Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.

Yifat Merbl (Y)

Department of Immunology , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.

Nir London (N)

Department of Organic Chemistry , The Weizmann Institute of Science , Rehovot , 7610001 , Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH